MX2017013805A - Composiciones de acido obeticolico y metodos de uso. - Google Patents

Composiciones de acido obeticolico y metodos de uso.

Info

Publication number
MX2017013805A
MX2017013805A MX2017013805A MX2017013805A MX2017013805A MX 2017013805 A MX2017013805 A MX 2017013805A MX 2017013805 A MX2017013805 A MX 2017013805A MX 2017013805 A MX2017013805 A MX 2017013805A MX 2017013805 A MX2017013805 A MX 2017013805A
Authority
MX
Mexico
Prior art keywords
methods
compositions
obeticolic acid
acid
obeticolic
Prior art date
Application number
MX2017013805A
Other languages
English (en)
Spanish (es)
Inventor
Shapiro David
Pruzanski Mark
G Lancaster Richard
K Olmstead Kay
Kagihiro Masashi
Taoka Ikuko
Matono Mitsuhiro
Pencek Richard
Sciacca Cathi
Eliot Lise
Edwards Jeffrey
A Macconell Leigh
K Marmon Tonya
Hooshmand-Rad Roya
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57198868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017013805(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of MX2017013805A publication Critical patent/MX2017013805A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017013805A 2015-04-27 2016-04-26 Composiciones de acido obeticolico y metodos de uso. MX2017013805A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562153040P 2015-04-27 2015-04-27
US201662317933P 2016-04-04 2016-04-04
PCT/US2016/029369 WO2016176208A1 (en) 2015-04-27 2016-04-26 Compositions of obeticholic acid and methods of use

Publications (1)

Publication Number Publication Date
MX2017013805A true MX2017013805A (es) 2018-09-06

Family

ID=57198868

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013805A MX2017013805A (es) 2015-04-27 2016-04-26 Composiciones de acido obeticolico y metodos de uso.

Country Status (25)

Country Link
US (9) US10052337B2 (cg-RX-API-DMAC7.html)
EP (3) EP4371616A3 (cg-RX-API-DMAC7.html)
JP (2) JP6941057B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170140325A (cg-RX-API-DMAC7.html)
CN (1) CN107531742A (cg-RX-API-DMAC7.html)
AU (2) AU2016255045B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017023161A2 (cg-RX-API-DMAC7.html)
CA (1) CA2983609C (cg-RX-API-DMAC7.html)
CL (1) CL2017002727A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017011535A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170492A (cg-RX-API-DMAC7.html)
EA (1) EA201792354A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP17078433A (cg-RX-API-DMAC7.html)
IL (2) IL294575A (cg-RX-API-DMAC7.html)
MA (1) MA41999A (cg-RX-API-DMAC7.html)
MX (1) MX2017013805A (cg-RX-API-DMAC7.html)
NI (1) NI201700128A (cg-RX-API-DMAC7.html)
PE (1) PE20180690A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017501956A1 (cg-RX-API-DMAC7.html)
SG (2) SG10202003110PA (cg-RX-API-DMAC7.html)
SV (1) SV2017005555A (cg-RX-API-DMAC7.html)
TN (1) TN2017000452A1 (cg-RX-API-DMAC7.html)
TW (1) TWI723017B (cg-RX-API-DMAC7.html)
WO (1) WO2016176208A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201707981B (cg-RX-API-DMAC7.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
ES2860423T3 (es) 2014-05-28 2021-10-05 Childrens Hospital Med Ct Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
EP3437645B1 (en) * 2016-03-31 2021-09-22 Intercept Pharmaceuticals, Inc. Film-coated tablet having high chemical stability of active ingredient
CA3020698A1 (en) * 2016-04-13 2017-10-19 Intercept Pharmaceuticals, Inc. Methods of treating or preventing hepatocellular carcinoma
CN109415685B (zh) 2016-05-05 2023-07-04 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
CN109640981A (zh) * 2016-06-29 2019-04-16 曼隆治疗公司 神经激肽-1拮抗剂用于治疗多种瘙痒病症的用途
SG10202104575WA (en) * 2016-11-04 2021-06-29 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
CN108072729A (zh) * 2016-11-18 2018-05-25 华北制药集团新药研究开发有限责任公司 一种测定奥贝胆酸片溶出度的方法
CA3045145A1 (en) 2016-12-05 2018-06-14 Children's Hospital Medical Center Colonic organoids and methods of making and using same
CN108614038B (zh) * 2016-12-13 2022-05-17 亚宝药业集团股份有限公司 一种测定奥贝胆酸原料药有关物质的方法
CN106645497A (zh) * 2017-01-03 2017-05-10 山东省药学科学院 一种奥贝胆酸及其制剂中有关物质的检测方法
TW201832768A (zh) * 2017-03-07 2018-09-16 英特賽普醫藥品公司 治療癌症的方法
US12281334B2 (en) 2017-04-14 2025-04-22 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
CA3070837A1 (en) 2017-07-24 2019-01-31 Intercept Pharmaceuticals, Inc. Isotopically labeled bile acid derivatives
WO2019074793A1 (en) 2017-10-10 2019-04-18 Children's Hospital Medical Center OESOPHAGIAN TISSUE COMPOSITIONS AND / OR ORGANOIDS AND METHODS OF MAKING SAME
WO2019106043A1 (en) * 2017-11-29 2019-06-06 Hexal Ag Pharmaceutical composition comprising obeticholic acid
US12379372B2 (en) 2017-12-21 2025-08-05 Children's Hospital Medical Center Digitalized human organoids and methods of using same
CN108572251B (zh) * 2018-05-31 2020-01-17 中国科学院昆明动物研究所 肝硬化早期小分子标志物及其应用
CA3106634A1 (en) 2018-07-26 2020-01-30 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
CN112823012A (zh) 2018-09-12 2021-05-18 儿童医院医学中心 用于产生造血干细胞及其衍生物的类器官组合物
CA3117966A1 (en) * 2018-11-08 2020-05-14 Intercept Pharmaceuticals, Inc. Methods of using obeticholic acid
CN109432431B (zh) * 2018-12-14 2020-06-30 中国药科大学 一种含有sumo抑制剂的组合物及应用
CN109655571B (zh) * 2019-01-08 2021-07-13 丽珠集团新北江制药股份有限公司 一种奥贝胆酸的高效液相色谱分析方法
CN109620812B (zh) * 2019-01-16 2023-07-21 浙江华海药业股份有限公司 一种奥贝胆酸组合物的制备方法
WO2020160371A1 (en) 2019-02-01 2020-08-06 The University Of Hong Kong Innervated organoid compositions and methods of making same
WO2020198383A1 (en) * 2019-03-26 2020-10-01 Intercept Pharmaceuticals, Inc. Methods of diagnosis and treatment of liver diseases using obeticholic acid
WO2020198576A1 (en) * 2019-03-28 2020-10-01 The Board Of Trustees Of The University Of Illinois Methods of modulating regulatory t cells
CA3141807A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
US12534709B2 (en) 2019-05-31 2026-01-27 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
CN114502198A (zh) * 2019-09-30 2022-05-13 诺华股份有限公司 包括使用fxr激动剂的治疗
EP4116710A4 (en) * 2020-03-06 2024-04-24 Mili Healthcare Trade DMCC, Limited Liability Company APPLICATION OF A GROUP OF MARKERS FOR DIAGNOSIS AND TREATMENT MODIFICATION OF PRIMARY BILIARY CHOLANGITIS, PHARMACEUTICAL COMPOSITION, AND SOLID DOSAGE FORM FOR THE TREATMENT OF PRIMITIVE BILIARY CHOLANGITIS
CN111518152B (zh) * 2020-04-23 2022-11-22 江西青峰药业有限公司 一种3α,7α-二羟基-6α-乙基-5β-胆烷-24-醛的制备方法及其应用
US20230201222A1 (en) * 2020-05-13 2023-06-29 Children's Hospital Medical Center Alleviation of liver injury by activating the signaling pathway mediated by farnesoid x receptor
CN111690731B (zh) * 2020-05-22 2021-09-28 河南大学 Fxr激动剂在治疗肝性脑病中的应用
CN111812264B (zh) * 2020-07-09 2021-06-15 苏州旭辉检测有限公司 一种去氧胆酸类化合物的生物样品分析方法
WO2022051321A1 (en) 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a fxr agonist
WO2022076683A1 (en) * 2020-10-07 2022-04-14 Intercept Pharmaceuticals, Inc. Methods of treating coronaviral infection with obeticholic acid
CN113143950B (zh) * 2021-05-17 2023-04-18 河北医科大学第二医院 一种治疗肝病的药物组合物及其应用
WO2023147141A1 (en) * 2022-01-28 2023-08-03 Intercept Pharmaceuticals, Inc. Combination therapy
WO2023181077A1 (en) * 2022-03-24 2023-09-28 Zenvision Pharma Llp Stable liquid composition comprising obeticholic acid or salts thereof
US12343351B2 (en) 2022-03-25 2025-07-01 Rutgers, The State University Of New Jersey Pulmonary function treatment
KR20250006156A (ko) * 2022-04-21 2025-01-10 인터셉트 파마슈티컬즈, 인크. 파르네소이드 x 수용체 효능제의 용도
US20260183243A1 (en) * 2022-07-25 2026-07-02 Shilpa Medicare Limited Pharmaceutical compositions of nor-udca
WO2024043842A1 (en) * 2022-08-22 2024-02-29 Pharmactive Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions comprising chenodeoxycholic acid (cdca) as active ingredient and other relevant excipients
WO2024104960A1 (en) 2022-11-15 2024-05-23 Synthon B.V. Stable formulation comprising obeticholic acid

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
ZA876640B (en) * 1986-09-26 1988-03-08 Warner-Lambert Company Treated lipid regulator
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
US7078376B1 (en) * 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
DK1392714T3 (da) * 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroider som agonister for FXR
CN100350977C (zh) 2001-06-14 2007-11-28 大塚制药株式会社 药物组合物
US6933380B2 (en) 2001-10-19 2005-08-23 Yung-Zip Chemical Ind. Co., Ltd. Excipients containing low residual solvent and method for producing the same
JP2006509722A (ja) * 2002-07-03 2006-03-23 エスペリオン セラピューティクス，インコーポレイテッド 脂質代謝異常を治療するためのパンテチン含有組成物
US20050101505A1 (en) * 2003-11-06 2005-05-12 Daniel Wood Liquid laundry detergent composition having improved color-care properties
GB0402492D0 (en) 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US8074906B2 (en) 2005-07-07 2011-12-13 Nanotherapeutics, Inc. Process for milling and preparing powders and compositions produced thereby
DE102007009242A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
JP2012520866A (ja) * 2009-03-17 2012-09-10 アプタリス・ファーマ・カナダ・インコーポレイテッド 高用量のウルソデオキシコール酸で非アルコール性脂肪性肝炎を治療する方法
CA2759109A1 (en) 2009-04-24 2010-10-28 Iceutica Pty Ltd A solid dosage form of ciprofloxacin having small particle size and improved powder handling characteristics
BR112012026843A2 (pt) 2010-04-20 2016-07-12 Cipla Ltd composição, composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição e método para tratamento de hiv
ES2822375T3 (es) * 2012-06-19 2021-04-30 Intercept Pharmaceuticals Inc Preparación de la forma no cristalina del ácido obeticólico
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
KR20150127599A (ko) 2013-03-15 2015-11-17 모치다 세이야쿠 가부시키가이샤 비알코올성 지방간염을 치료하기 위한 조성물 및 방법
CN105377870B (zh) 2013-05-14 2018-04-03 英特塞普特医药品公司 作为法尼醇x受体调节剂的胆汁酸的11‑羟基衍生物及其氨基酸共轭物
MX377523B (es) 2013-09-11 2025-03-10 Inst Nat Sante Rech Med Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b.
CN105801653B (zh) 2014-12-30 2018-04-17 苏州晶云药物科技有限公司 奥贝胆酸的晶型a及其制备方法
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso

Also Published As

Publication number Publication date
EP3971199A1 (en) 2022-03-23
WO2016176208A1 (en) 2016-11-03
TN2017000452A1 (en) 2019-04-12
PH12017501956A1 (en) 2018-03-26
AU2016255045B2 (en) 2020-04-16
US10052337B2 (en) 2018-08-21
SG10202003110PA (en) 2020-05-28
KR20170140325A (ko) 2017-12-20
EP4371616A3 (en) 2024-08-28
AU2020205315A1 (en) 2020-08-06
US20220133745A1 (en) 2022-05-05
IL255269A (en) 2018-02-28
ECSP17078433A (es) 2018-02-28
EP3288958A4 (en) 2018-09-26
EP4371616A2 (en) 2024-05-22
JP2021183651A (ja) 2021-12-02
JP2018514534A (ja) 2018-06-07
PE20180690A1 (es) 2018-04-23
US20200054650A1 (en) 2020-02-20
US20200046735A1 (en) 2020-02-13
JP6941057B2 (ja) 2021-09-29
ZA201707981B (en) 2019-03-27
US20190255071A1 (en) 2019-08-22
SV2017005555A (es) 2019-01-18
CO2017011535A2 (es) 2018-01-31
US20190076446A1 (en) 2019-03-14
US10758549B2 (en) 2020-09-01
CA2983609A1 (en) 2016-11-03
TWI723017B (zh) 2021-04-01
US20170035784A1 (en) 2017-02-09
EP3288958A1 (en) 2018-03-07
SG11201708606VA (en) 2017-11-29
NI201700128A (es) 2018-04-11
AU2016255045A1 (en) 2017-11-09
US10646499B2 (en) 2020-05-12
CN107531742A (zh) 2018-01-02
US20200171053A1 (en) 2020-06-04
MA41999A (fr) 2018-03-07
CA2983609C (en) 2024-05-07
US20200046736A1 (en) 2020-02-13
US20260000682A1 (en) 2026-01-01
CL2017002727A1 (es) 2018-04-27
BR112017023161A2 (pt) 2018-07-24
CR20170492A (es) 2018-05-15
IL255269B (en) 2022-08-01
EA201792354A1 (ru) 2018-03-30
US10751349B2 (en) 2020-08-25
IL294575A (en) 2022-09-01
TW201703773A (zh) 2017-02-01

Similar Documents

Publication Publication Date Title
CO2017011535A2 (es) Composiciones de ácido obeticólico y métodos de uso
CL2020000946A1 (es) Métodos y composiciones para la producción de trifosfato de nucleosido y ácido ribonucleico
CL2018001056A1 (es) Vacuna contra el virus herpes simplex
MX389349B (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
MX2018007022A (es) Metodos para tratar la enfermedad de huntington.
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
CO2017002253A2 (es) Compuesto dirigido a il-23a y tnf-alfa
MX2016010213A (es) Formulaciones farmaceuticas novedosas.
MX2016006271A (es) Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
MX374191B (es) Derivados de nucleósido sustituidos con 4´ -difluorometilo como inhibidores de la replicación de arn de la influenza.
MX2021000773A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo.
UY35796A (es) ?derivados de dihidrohidantoína sustituidos, procesos para prepararlos, composiciones herbicidas y su uso en plantas?.
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
CO2017002506A2 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
MX384877B (es) Composiciones de éster de colina de ácido lipoico y métodos de uso.
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
CL2019002729A1 (es) Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico.
CO2019008110A2 (es) Activador de nrf2
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas